register

News & Trends - Pharmaceuticals

BMS/Celgene merger heads to a close after clearance from competition regulators

Health Industry Hub | November 20, 2019 |

Bristol-Myers Squibb announced the approval from the U.S. Federal Trade Commission (FTC) to close the pending $74bn merger of Bristol-Myers Squibb and Celgene.

The merger could create the fourth largest pharma firm by revenue, behind Pfizer, Novartis, and Roche.

Celgene entered into an agreement with Amgen under which Amgen would acquire the global rights to psoriasis drug OTEZLA (apremilast). Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for Bristol-Myers Squibb’s pending merger with Celgene.

Bristol-Myers Squibb has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on November 20, 2019. Bristol-Myers Squibb also expects the OTEZLA divestiture to be completed promptly following the closing of the merger.

“Today’s news is an exciting milestone in our company’s history as we look forward to officially combining with Celgene to create a leading biopharma company,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together we will be well positioned to discover, develop and deliver innovative medicines, and to transform the lives of more patients through science.”

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like 91% of clinicians use reprints to improve patient care


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.